Moleculin Nears Key MIRACLE AML Trial Data Milestone
HOUSTON, May 15, 2026 Moleculin Biotech reported first quarter 2026 financial results while advancing its pivotal MIRACLE Phase 2B/3...
Biotech
Advertisement
Tenaya Gene Therapy Shows Strong Arrhythmia Reduction in ARVC Trial
SOUTH SAN FRANCISCO, Calif., May 15, 2026 Tenaya Therapeutics reported encouraging interim Phase 1b/2 clinical data for TN-401, its...
Enliven Therapeutics Reports Strong ELVN-001 CML Data
BOULDER, Colo., May 12, 2026 Enliven Therapeutics announced new positive clinical findings from its ongoing Phase 1 ENABLE trial...
Allogene to Reveal ALPHA3 CAR-T Trial Data Soon
South San Francisco, California | April 10, 2026 Allogene Therapeutics has announced that it will present the interim futility...
Elanco Leader Joins Neurizon to Boost ALS Drug Program
MELBOURNE, Australia – Nov. 26, 2025 — Neurizon Therapeutics (ASX: NUZ & NUZOA; OTCQB: NUZTF), a clinical-stage biotech firm...
Advertisements
FDA Clears Tonix IND for TNX-102 SL in Major Depression
Chatham, New Jersey, November 24, 2025 — Tonix Pharmaceuticals announced that the U.S. Food & Drug Administration has cleared...
OS Therapies Spins Off OS Animal Health as New Veterinary Biotech
ROCKVILLE, MD — November 20, 2025 — OS Therapies announced the strategic spin-off of OS Animal Health, establishing it...
Kezar Advances Zetomipzomib After FDA Lifts Trial Hold
SOUTH SAN FRANCISCO, Calif.,—Kezar Life Sciences has reported its second-quarter 2025 financial results alongside a notable series of regulatory...
FDA Grants Orphan Drug Status to Cellenkos’ CK0803 for ALS Treatment
HOUSTON, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
Advertisement
